Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MLLCF MOLECULAR PARTNERS AG
6.4500.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-33.74% 2.34M 265.64% 11.75M 21,099.75% 172.78M -0.15% 9.33M
Operating revenue
-33.74% 2.34M 265.64% 11.75M 21,099.75% 172.78M -0.15% 9.33M
Cost of revenue
Gross profit
Operating expense
4.06% 17.03M -7.36% 18.04M 4.54% 20.22M 7.51% 72.75M
Selling and administrative expenses
18.60% 5.56M 27.89% 5.48M 72.16% 5.76M 53.31% 16.91M
-General and administrative expense
-- -- -- -- -- -- 53.31% 16.91M
Research and development costs
-1.59% 11.5M -18.47% 12.57M -10.46% 14.47M -0.64% 55.72M
Depreciation amortization depletion
-- -- -- -- -- -- -3.35% 549K
-Depreciation and amortization
-- -- -- -- -- -- -3.35% 549K
Other operating expenses
-350.00% -27K 96.04% -9K 96.91% -5K -- -424K
Operating profit
-14.45% -14.69M 61.30% -6.29M 923.28% 152.55M -8.73% -63.42M
Net non-operating interest income expense
251.65% 138K 35.61% -85K 5.29% -161K -814.06% -457K
Non-operating interest income
537.50% 255K 1,460.00% 156K 1,157.14% 88K -73.02% 99K
Non-operating interest expense
-13.18% 112K 70.00% 238K 41.14% 247K 102.21% 548K
Total other finance cost
150.00% 5K 50.00% 3K 0.00% 2K -75.00% 8K
Other net income (expense)
99.03% 1.23M 400.32% 1.86M -65.75% 735K 102.04% 92K
Gain on sale of security
99.03% 1.23M 400.32% 1.86M -65.75% 735K 102.04% 92K
Income before tax
-8.23% -13.32M 73.42% -4.52M 1,025.02% 153.13M -1.61% -63.78M
Income tax
0 0 0 118.18% 2K
Net income
-8.23% -13.32M 73.42% -4.52M 1,025.02% 153.13M -1.63% -63.79M
Net income continuous Operations
-8.23% -13.32M 73.42% -4.52M 1,025.02% 153.13M -1.63% -63.79M
Minority interest income
Net income attributable to the parent company
-8.23% -13.32M 73.42% -4.52M 1,025.02% 153.13M -1.63% -63.79M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-8.23% -13.32M 73.42% -4.52M 1,025.02% 153.13M -1.63% -63.79M
Basic earnings per share
-7.89% -0.41 65.12% -0.15 931.58% 4.74 17.93% -2.06
Diluted earnings per share
-7.89% -0.41 65.12% -0.15 910.53% 4.62 17.93% -2.06
Dividend per share
Currency Unit
CHFCHFCHFCHF
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
CEO: Dr. Patrick Amstutz, PhD
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist